Presented by Johns Hopkins Carey Business School and the Hopkins Business of Health Initiative
COVID-19 Vaccine: From Discovery to Delivery
The development and deployment of an effective vaccine for COVID-19 could be the turning point in the fight against the deadly pandemic. Join our distinguished panel of public health experts and vaccine industry executives for an engaging discussion examining every aspect of the COVID-19 vaccine from discovery to manufacturing to delivery.
Registration for this event is open to the entire Carey Business School community, Johns Hopkins community, and the general public. Please share widely with your networks.
Bill Enright is the chief executive officer of Vaccitech, a strategic partner with AstraZeneca in developing one of the first COVID-19 vaccine candidates. He is also a graduate of Johns Hopkins Carey Business School and a member of the Dean’s Advisory Board.
Abigail Jenkins is senior vice president and vaccine business unit head for Emergent BioSolutions, where she has global, end-to-end responsibility for the commercialization of their vaccine portfolio. Abbey earned an MS in Biotechnology & Biotech Business Enterprise from Johns Hopkins University. Emergent has responded to the COVID pandemic by providing contract development and manufacturing (CDMO) services to government and pharma and biotech customers, as well as by developing their own plasma-based therapeutic candidates.
Daniel Polsky, PhD, is Bloomberg Distinguished Professor in Health Economics at Johns Hopkins Carey Business School and Johns Hopkins Bloomberg School of Public Health. He also directs the Hopkins Business of Health Initiative and will serve as moderator of the panel.
Reed Tuckson, MD, FACP, is the managing director of Tuckson Health Connections, LLC. Previously he was executive vice president and chief of medical affairs for United Health Group and commissioner of public health for Washington, D.C.